Skip to main content

Advertisement

SpringerLink
Log in

Predictive value of GSTP1 Ile105Val polymorphism in clinical outcomes of chemotherapy in gastric and colorectal cancers: a systematic review and meta-analysis

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

Gastric and colorectal cancers remain the major causes of cancer-related death with a bad prognosis. Up to now, platinum combined with fluoropyrimidines has been most commonly used in chemotherapy regimens of gastric and colorectal cancers. Recently, a series of studies have been conducted to investigate the associations of biomarkers, such as GSTP1 Ile105Val polymorphism, with the chemotherapy efficacy in gastric and colorectal cancers; however, the results were not consistent and inconclusive. Here, we performed a systematic review and meta-analysis to summarize the associations of GSTP1 Ile105Val polymorphism with the chemotherapy efficacy in gastric and colorectal cancers.

Methods

A systematic review was conducted to search relevant studies in English databases (PubMed, ISI Web of Science, and EMBASE) up to November 30, 2015. The pooling ORs or HRs were used to assess the strength of the associations of GSTP1 Ile105Val polymorphism with clinical outcomes such as tumor response, toxicity, progression-free survival (PFS), and overall survival (OS).

Results

Forty-one papers containing 8169 cases were finally included in the present meta-analysis study. Of which, 28 articles were performed in colorectal cancers, one in gastrointestinal carcinoma (gastric and colon cancer), 11 in gastric cancers, and one in colorectal and gastroesophageal cancers. After pooling all the eligible studies, we identified significant associations of GSTP1 Ile105Val polymorphism with chemotherapy-related tumor response (G vs. A: OR 1.697, 95 % CI 1.191–2.418; GG vs. AA: OR 2.804, 95 % CI 1.414–5.560; AG vs. AA: OR 1.540, 95 % CI 1.011–2.347; GG vs. AAAG: OR 2.139, 95 % CI 1.256–3.641), PFS (GG vs. AA, HR 0.640, 95 % CI 0.455–0.900; AGGG vs. AA: HR 0.718, 95 % CI 0.562–0.919), and OS (AG vs. AA: HR 0.857, 95 % CI 0.746–0.986; GG vs. AA: HR 0.679, 95 % CI 0.523–0.882; AGGG vs. AA: HR 0.663, 95 % CI 0.542–0.812) in gastric and colorectal cancers and no significant association was found between the polymorphism with toxicity.

Conclusions

GSTP1 Ile105Val polymorphism was associated with tumor response, PFS, and OS in gastric and colorectal cancers after chemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2008) Cancer statistics, 2008. CA Cancer J Clin 58(2):71–96. doi:10.3322/CA.2007.0010

    Article  PubMed  Google Scholar 

  2. Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64(1):9–29. doi:10.3322/caac.21208

    Article  PubMed  Google Scholar 

  3. Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24(14):2137–2150. doi:10.1200/JCO.2005.05.2308

    Article  PubMed  Google Scholar 

  4. Macdonald JS (2004) Treatment of localized gastric cancer. Semin Oncol 31(4):566–573

    Article  CAS  PubMed  Google Scholar 

  5. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE (2006) Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 24(18):2903–2909. doi:10.1200/JCO.2005.05.0245

    Article  CAS  PubMed  Google Scholar 

  6. Wagner AD, Unverzagt S, Grothe W, Kleber G, Grothey A, Haerting J, Fleig WE (2010) Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev (3):CD004064. doi:10.1002/14651858.CD004064.pub3

  7. Wohrer SS, Raderer M, Hejna M (2004) Palliative chemotherapy for advanced gastric cancer. Ann Oncol 15(11):1585–1595. doi:10.1093/annonc/mdh422

    Article  CAS  PubMed  Google Scholar 

  8. Xu R, Ma N, Wang F, Ma L, Chen R, Chen R, Kebinu M, Ma L, Han Z, Ayixiamu MM, Su P, Naman Y, Jieensi H, Yang H, Adili A, Aili S, Liu J (2013) Results of a randomized and controlled clinical trial evaluating the efficacy and safety of combination therapy with Endostar and S-1 combined with oxaliplatin in advanced gastric cancer. OncoTargets Ther 6:925–929. doi:10.2147/OTT.S46487

    CAS  Google Scholar 

  9. Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho JY, Mok YJ, Kim YH, Ji J, Yeh TS, Button P, Sirzen F, Noh SH, Investigators Ct (2012) Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 379(9813):315–321. doi:10.1016/S0140-6736(11)61873-4

    Article  CAS  PubMed  Google Scholar 

  10. Cassidy J, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Rittweger K, Gilberg F, Saltz L (2011) XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. Br J Cancer 105(1):58–64. doi:10.1038/bjc.2011.201

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Chua W, Kho PS, Moore MM, Charles KA, Clarke SJ (2011) Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer. Crit Rev Oncol Hematol 79(3):224–250. doi:10.1016/j.critrevonc.2010.07.012

    Article  PubMed  Google Scholar 

  12. Cortejoso L, Lopez-Fernandez LA (2012) Pharmacogenetic markers of toxicity for chemotherapy in colorectal cancer patients. Pharmacogenomics 13(10):1173–1191. doi:10.2217/pgs.12.95

    Article  CAS  PubMed  Google Scholar 

  13. Goekkurt E, Hoehn S, Wolschke C, Wittmer C, Stueber C, Hossfeld DK, Stoehlmacher J (2006) Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)—novel predictors for response and survival in gastric cancer patients. Br J Cancer 94(2):281–286. doi:10.1038/sj.bjc.6602891

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Furuta T, Ueda T, Aune G, Sarasin A, Kraemer KH, Pommier Y (2002) Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res 62(17):4899–4902

    CAS  PubMed  Google Scholar 

  15. Sohn KJ, Croxford R, Yates Z, Lucock M, Kim YI (2004) Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. J Natl Cancer Inst 96(2):134–144

    Article  CAS  PubMed  Google Scholar 

  16. Peklak-Scott C, Smitherman PK, Townsend AJ, Morrow CS (2008) Role of glutathione S-transferase P1-1 in the cellular detoxification of cisplatin. Mol Cancer Ther 7(10):3247–3255. doi:10.1158/1535-7163.MCT-08-0250

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Karam RA, Pasha HF, El-Shal AS, Rahman HM, Gad DM (2012) Impact of glutathione-S-transferase gene polymorphisms on enzyme activity, lung function and bronchial asthma susceptibility in Egyptian children. Gene 497(2):314–319. doi:10.1016/j.gene.2012.01.059

    Article  CAS  PubMed  Google Scholar 

  18. Wang Y, Zeng T (2013) Response to: Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 14:391. doi:10.1186/1745-6215-14-391

    Article  PubMed  PubMed Central  Google Scholar 

  19. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8:16. doi:10.1186/1745-6215-8-16

    Article  PubMed  PubMed Central  Google Scholar 

  20. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188

    Article  CAS  PubMed  Google Scholar 

  21. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50(4):1088–1101

    Article  CAS  PubMed  Google Scholar 

  22. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629–634

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Stoehlmacher J, Park DJ, Zhang W, Groshen S, Tsao-Wei DD, Yu MC, Lenz HJ (2002) Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 94(12):936–942

    Article  CAS  PubMed  Google Scholar 

  24. Lecomte T, Landi B, Beaune P, Laurent-Puig P, Loriot MA (2006) Glutathione S-transferase P1 polymorphism (Ile(105)Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin Cancer Res 12(10):3050–3056. doi:10.1158/1078-0432.ccr-05-2076

    Article  CAS  PubMed  Google Scholar 

  25. Ruzzo A, Graziano F, Kawakami K, Watanabe G, Santini D, Catalano V, Bisonni R, Canestrari E, Ficarelli R, Menichetti ET, Mari D, Testa E, Silva R, Vincenzi B, Giordani P, Cascinu S, Giustini L, Tonini G, Magnani M (2006) Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy. J Clin Oncol 24(12):1883–1891. doi:10.1200/jco.2005.04.8322

    Article  CAS  PubMed  Google Scholar 

  26. Gamelin L, Capitain O, Morel A, Dumont A, Traore S, Anne LB, Gilles S, Boisdron-Celle M, Gamelin E (2007) Predictive factors of oxaliplatin neurotoxicity: the involvement of the oxalate outcome pathway. Clin Cancer Res 13(21):6359–6368

    Article  CAS  PubMed  Google Scholar 

  27. Le Morvan V, Smith D, Laurand A, Brouste V, Bellott R, Soubeyran I, Mathoulin-Pelissier S, Robert J (2007) Determination of ERCC2 Lys751G1n and GSTP1Ile105Va1 gene polymorphisms in colorectal cancer patients: relationships with treatment outcome. Pharmacogenomics 8(12):1693–1703

    Article  PubMed  Google Scholar 

  28. Ruzzo A, Graziano F, Loupakis F, Rulli E, Canestrari E, Santini D, Catalano V, Ficarelli R, Maltese P, Bisonni R, Masi G, Schiavon G, Giordani P, Giustini L, Falcone A, Tonini G, Silva R, Mattioli R, Floriani I, Magnani M (2007) Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol 25(10):1247–1254. doi:10.1200/jco.2006.08.1844

    Article  CAS  PubMed  Google Scholar 

  29. Keam B, Im SA, Han SW, Ham HS, Kim MA, Oh DY, Lee SH, Kim JH, Kim DW, Kim TY, Heo DS, Kim WH, Bang YJ (2008) Modified FOLFOX-6 chemotherapy in advanced gastric cancer: results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker. BMC Cancer 8:148. doi:10.1186/1471-2407-8-148

    Article  PubMed  PubMed Central  Google Scholar 

  30. Kweekel DM, Koopman M, Antonini NF, Van der Straaten T, Nortier JW, Gelderblom H, Punt CJ, Guchelaar HJ (2008) GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group. Br J Cancer 99(8):1316–1321. doi:10.1038/sj.bjc.6604654

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Ott K, Lordick F, Becker K, Ulm K, Siewert JR, Höfler H, Keller G (2008) Glutathione-S -transferase P1, T1 and M1 genetic polymorphisms in neoadjuvant-treated locally advanced gastric cancer: GSTM1-present genotype is associated with better prognosis in completely resected patients. Int J Colorectal Dis 23(8):773–782

    Article  PubMed  Google Scholar 

  32. Pare L, Marcuello E, Altes A, del Rio E, Sedano L, Salazar J, Cortes A, Barnadas A, Baiget M (2008) Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy. Br J Cancer 99(7):1050–1055. doi:10.1038/sj.bjc.6604671

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Braun MS, Richman SD, Thompson L, Daly CL, Meade AM, Adlard JW, Allan JM, Parmar MK, Quirke P, Seymour MT (2009) Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial. J Clin Oncol 27(33):5519–5528. doi:10.1200/jco.2008.21.6283

    Article  CAS  PubMed  Google Scholar 

  34. Goekkurt E, Al-Batran SE, Hartmann JT, Mogck U, Schuch G, Kramer M, Jaeger E, Bokemeyer C, Ehninger G, Stoehlmacher J (2009) Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie. J Clin Oncol 27(17):2863–2873. doi:10.1200/JCO.2008.19.1718

    Article  CAS  PubMed  Google Scholar 

  35. Huang ZH, Hua D, Du X (2009) Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy. Cancer Chemother Pharmacol 64(5):1001–1007. doi:10.1007/s00280-009-0956-2

    Article  CAS  PubMed  Google Scholar 

  36. Kweekel DM, Gelderblom H, Antonini NF, Van der Straaten T, Nortier JW, Punt CJ, Guchelaar HJ (2009) Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients. Eur J Cancer (Oxf Engl 1990) 45(4):572–578. doi:10.1016/j.ejca.2008.10.015

    Article  CAS  Google Scholar 

  37. Liang J, Zhang H, Yin B (2009) Genetic polymorphisms of GSTP1 related to response to 5-FU-oxaliplatin- based chemotherapy and clinical outcome in advanced colorectal cancer patients. Swiss Med Wkly 139(49–50):724–728

    CAS  Google Scholar 

  38. Seo BG, Kwon HC, Oh SY, Lee S, Kim SG, Kim SH, Han H, Kim HJ (2009) Comprehensive analysis of excision repair complementation group 1, glutathione S-transferase, thymidylate synthase and uridine diphosphate glucuronosyl transferase 1A1 polymorphisms predictive for treatment outcome in patients with advanced gastric cancer treated with FOLFOX or FOLFIRI. Oncol Rep 22(1):127–136

    CAS  PubMed  Google Scholar 

  39. Boige V, Mendiboure J, Pignon JP, Loriot MA, Castaing M, Barrois M, Malka D, Tregouet DA, Bouche O, Le Corre D, Miran I, Mulot C, Ducreux M, Beaune P, Laurent-Puig P (2010) Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000–2005. J Clin Oncol 28(15):2556–2564. doi:10.1200/JCO.2009.25.2106

    Article  CAS  PubMed  Google Scholar 

  40. Chen YC, Tzeng CH, Chen PM, Lin JK, Lin TC, Chen WS, Jiang JK, Wang HS, Wang WS (2010) Influence of GSTP1 I105 V polymorphism on cumulative neuropathy and outcome of FOLFOX-4 treatment in Asian patients with colorectal carcinoma. Cancer Sci 101(2):530–535

    Article  CAS  PubMed  Google Scholar 

  41. Etienne-Grimaldi MC, Milano G, Maindrault-Goebel F, Chibaudel B, Formento JL, Francoual M, Lledo G, Andre T, Mabro M, Mineur L, Flesch M, Carola E, de Gramont A (2010) Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients. Br J Clin Pharmacol 69(1):58–66. doi:10.1111/j.1365-2125.2009.03556.x

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Funke S, Timofeeva M, Risch A, Hoffmeister M, Stegmaier C, Seiler CM, Brenner H, Chang-Claude J (2010) Genetic polymorphisms in GST genes and survival of colorectal cancer patients treated with chemotherapy. Pharmacogenomics 11(1):33–41. doi:10.2217/pgs.09.132

    Article  CAS  PubMed  Google Scholar 

  43. Inada M, Sato M, Morita S, Kitagawa K, Kawada K, Mitsuma A, Sawaki M, Fujita K, Ando Y (2010) Associations between oxaliplatin-induced peripheral neuropathy and polymorphisms of the ERCC1 and GSTP1 genes. Int J Clin Pharmacol Ther 48(11):729–734

    Article  CAS  PubMed  Google Scholar 

  44. Kanai M, Yoshioka A, Tanaka S, Nagayama S, Matsumoto S, Nishimura T, Niimi M, Teramukai S, Takahashi R, Mori Y, Kitano T, Ishiguroa H, Yanagihara K, Chiba T, Fukushima M, Matsuda F (2010) Associations between glutathione S-transferase pi Ile(105)Val and glyoxylate aminotransferase Pro(11)Leu and Ile(340)Met polymorphisms and early-onset oxaliplatin-induced neuropathy. Cancer Epidemiol 34(2):189–193. doi:10.1016/j.canep.2010.02.008

    Article  CAS  PubMed  Google Scholar 

  45. Li Q-F, Yao R-Y, K-w L, Lv H-Y, Jiang T, Liang J (2010) Genetic Polymorphism of GSTP1: prediction of Clinical Outcome to Oxaliplatin/5-FU-based chemotherapy in advanced gastric cancer. J Korean Med Sci 25(6):846–852. doi:10.3346/jkms.2010.25.6.846

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. McLeod HL, Sargent DJ, Marsh S, Green EM, King CR, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Thibodeau SN, Grothey A, Morton RF, Goldberg RM (2010) Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. J Clin Oncol 28(20):3227–3233. doi:10.1200/JCO.2009.21.7943

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Shim HJ, Yun JY, Hwang JE, Bae WK, Cho SH, Lee JH, Kim HN, Shin MH, Kweon SS, Lee JH, Kim HJ, Chung IJ (2010) BRCA1 and XRCC1 polymorphisms associated with survival in advanced gastric cancer treated with taxane and cisplatin. Cancer Sci 101(5):1247–1254. doi:10.1111/j.1349-7006.2010.01514.x

    Article  CAS  PubMed  Google Scholar 

  48. Zarate R, Rodriguez J, Bandres E, Patino-Garcia A, Ponz-Sarvise M, Viudez A, Ramirez N, Bitarte N, Chopitea A, Gacia-Foncillas J (2010) Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis. Br J Cancer 102(6):987–994. doi:10.1038/sj.bjc.6605595

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Hong J, Han S-W, Ham HS, Kim T-Y, Choi IS, Kim B-S, Oh D-Y, Im S-A, Kang GH, Bang Y-J, Kim T-Y (2011) Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis. Cancer Chemother Pharmacol 67(6):1323–1331. doi:10.1007/s00280-010-1425-7

    Article  CAS  PubMed  Google Scholar 

  50. Huang MY, Huang ML, Chen MJ, Lu CY, Chen CF, Tsai PC, Chuang SC, Hou MF, Lin SR, Wang JY (2011) Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy. Pharmacogenet Genomics 21(1):18–25. doi:10.1097/FPC.0b013e3283415124

    Article  CAS  PubMed  Google Scholar 

  51. Lamas MJ, Duran G, Balboa E, Bernardez B, Touris M, Vidal Y, Gallardo E, Lopez R, Carracedo A, Barros F (2011) Use of a comprehensive panel of biomarkers to predict response to a fluorouracil-oxaliplatin regimen in patients with metastatic colorectal cancer. Pharmacogenomics 12(3):433–442. doi:10.2217/pgs.10.196

    Article  CAS  PubMed  Google Scholar 

  52. Li HY, Ge X, Huang GM, Li KY, Zhao JQ, Yu XM, Bi WS, Wang YL (2012) GSTP1, ERCC1 and ERCC2 polymorphisms, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in colorectal cancer in Chinese population. Asian Pac J Cancer Prev 13(7):3465–3469

    Article  PubMed  Google Scholar 

  53. Cecchin E, D’Andrea M, Lonardi S, Zanusso C, Pella N, Errante D, De Mattia E, Polesel J, Innocenti F, Toffoli G (2013) A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen. Pharmacogenomics J 13(5):403–409. doi:10.1038/tpj.2012.31

    Article  CAS  PubMed  Google Scholar 

  54. Ji M, Xu B, Jiang J-T, Wu J, Li X-D, Zhao W-Q, Zhang H-Y, Zhou W-J, Wu C-P (2013) Relationship between Glutathione S-transferase P1 (GSTP1), X-Ray Repair Cross Complementing Group 1 (XRCC1) and 5,10-methylenetetrahydrofolate Reductase (5,10-MTHFR) Gene Polymorphisms and Response to Chemotherapy in Advanced Gastric Cancer. Onkologie 36(6):335–340. doi:10.1159/000351260

    Article  CAS  PubMed  Google Scholar 

  55. Kumamoto K, Ishibashi K, Okada N, Tajima Y, Kuwabara K, Kumagai Y, Baba H, Haga N, Ishida H (2013) Polymorphisms of GSTP1, ERCC2 and TS-3′UTR are associated with the clinical outcome of mFOLFOX6 in colorectal cancer patients. Oncol Lett 6(3):648–654

    CAS  PubMed  PubMed Central  Google Scholar 

  56. Lai C-Y, Hsieh L-L, Sung F-C, Tang R, Bai C-H, Wu F-Y, Chiou H-Y, Yeh C-C (2013) Tumor site- and stage-specific associations between allelic variants of glutathione S-transferase and DNA-repair genes and overall survival in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. PLoS ONE. doi:10.1371/journal.pone.0069039

    Google Scholar 

  57. Liu YP, Ling Y, Qi QF, Zhang YP, Zhang CS, Zhu CT, Wang MH, Pan YD (2013) Genetic polymorphisms of ERCC1-118, XRCC1-399 and GSTP1-105 are associated with the clinical outcome of gastric cancer patients receiving oxaliplatin-based adjuvant chemotherapy. Mol Med Rep 7(6):1904–1911

    CAS  PubMed  Google Scholar 

  58. Nishina T, Takano Y, Denda T, Yasui H, Takeda K, Ura T, Esaki T, Okuyama Y, Kondo K, Takahashi Y, Sugiyama Y, Muro K (2013) A phase II clinical study of mFOLFOX6 plus bevacizumab as first-line therapy for Japanese advanced/recurrent colorectal cancer patients. Jpn J Clin Oncol 43(11):1080–1086. doi:10.1093/jjco/hyt127

    Article  PubMed  PubMed Central  Google Scholar 

  59. Kap EJ, Richter S, Rudolph A, Jansen L, Ulrich A, Hoffmeister M, Ulrich CM, Brenner H, Chang-Claude J (2014) Genetic variants in the glutathione S-transferase genes and survival in colorectal cancer patients after chemotherapy and differences according to treatment with oxaliplatin. Pharmacogenet Genomics 24(7):340–347. doi:10.1097/fpc.0000000000000059

    Article  CAS  PubMed  Google Scholar 

  60. Ruzzo A, Graziano F, Galli F, Giacomini E, Floriani I, Galli F, Rulli E, Lonardi S, Ronzoni M, Massidda B, Zagonel V, Pella N, Mucciarini C, Labianca R, Ionta MT, Veltri E, Sozzi P, Barni S, Ricci V, Foltran L, Nicolini M, Biondi E, Bramati A, Turci D, Lazzarelli S, Verusio C, Bergamo F, Sobrero A, Frontini L, Magnani M (2014) Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patients. Sci Rep 4:6828. doi:10.1038/srep06828

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Joerger M, Huitema ADR, Boot H, Cats A, Doodeman VD, Smits PHM, Vainchtein L, Rosing H, Meijerman I, Zueger M, Meulendijks D, Cerny TD, Beijnen JH, Schellens JHM (2015) Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy. Cancer Chemother Pharmacol 75(4):763–772. doi:10.1007/s00280-015-2698-7

    Article  CAS  PubMed  Google Scholar 

  62. Xu Z, Chen Y, Gu D, Lee NP, Sun S, Gong W, Tan Y, Luk JM, Chen J (2015) SOD2 rs4880 CT/CC genotype predicts poor survival for Chinese gastric cancer patients received platinum and fluorouracil based adjuvant chemotherapy. Am J Transl Res 7(2):401–410

    PubMed  PubMed Central  Google Scholar 

  63. Yin M, Yan J, Martinez-Balibrea E, Graziano F, Lenz HJ, Kim HJ, Robert J, Im SA, Wang WS, Etienne-Grimaldi MC, Wei Q (2011) ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis. Clin Cancer Res 17(6):1632–1640. doi:10.1158/1078-0432.ccr-10-2169

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Ma SC, Zhao Y, Zhang T, Ling XL, Zhao D (2015) Association between the ERCC1 rs11615 polymorphism and clinical outcomes of oxaliplatin-based chemotherapies in gastrointestinal cancer: a meta-analysis. OncoTargets Ther 8:641–648. doi:10.2147/ott.s80913

    Google Scholar 

  65. Liu X, Cheng D, Kuang Q, Liu G, Xu W (2013) Association between UGT1A1*28 polymorphisms and clinical outcomes of irinotecan-based chemotherapies in colorectal cancer: a meta-analysis in Caucasians. PLoS One 8(3):e58489. doi:10.1371/journal.pone.0058489

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Liu X, Cheng D, Kuang Q, Liu G, Xu W (2014) Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians. Pharmacogenomics J 14(2):120–129. doi:10.1038/tpj.2013.10

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Rosmarin D, Palles C, Church D, Domingo E, Jones A, Johnstone E, Wang H, Love S, Julier P, Scudder C, Nicholson G, Gonzalez-Neira A, Martin M, Sargent D, Green E, McLeod H, Zanger UM, Schwab M, Braun M, Seymour M, Thompson L, Lacas B, Boige V, Ribelles N, Afzal S, Enghusen H, Jensen SA, Etienne-Grimaldi MC, Milano G, Wadelius M, Glimelius B, Garmo H, Gusella M, Lecomte T, Laurent-Puig P, Martinez-Balibrea E, Sharma R, Garcia-Foncillas J, Kleibl Z, Morel A, Pignon JP, Midgley R, Kerr D, Tomlinson I (2014) Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. J Clin Oncol 32(10):1031–1039. doi:10.1200/jco.2013.51.1857

    Article  CAS  PubMed  Google Scholar 

  68. Cao Z, Song J, Wang J, Guo X, Yu S, Dong W (2014) Association between polymorphisms in XRCC1 gene and treatment outcomes of patients with advanced gastric cancer: a systematic review and meta-analysis. PLoS ONE 9(1):e85357. doi:10.1371/journal.pone.0085357

    Article  PubMed  PubMed Central  Google Scholar 

  69. Wang Z, Chen JQ, Liu JL, Qin XG, Huang Y (2012) Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum/5-Fu-based chemotherapy: a systematic review. BMC Gastroenterology 12:137. doi:10.1186/1471-230x-12-137

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Ye F, Liu Z, Tan A, Liao M, Mo Z, Yang X (2013) XRCC1 and GSTP1 polymorphisms and prognosis of oxaliplatin-based chemotherapy in colorectal cancer: a meta-analysis. Cancer Chemother Pharmacol 71(3):733–740. doi:10.1007/s00280-012-2067-8

    Article  CAS  PubMed  Google Scholar 

  71. Peng Z, Wang Q, Gao J, Ji Z, Yuan J, Tian Y, Shen L (2013) Association between GSTP1 Ile105Val polymorphism and oxaliplatin-induced neuropathy: a systematic review and meta-analysis. Cancer Chemother Pharmacol 72(2):305–314. doi:10.1007/s00280-013-2194-x

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by the grants from the National Natural Science Foundation of China (No. 81172619 and 81472940).

Author contributions

XBS and JW designed the study. JW, XLY and XFR searched databases and collected full-text papers. FW and XWC extracted and analyzed the data. XBS, JW and YCX were involved in statistical analyses. XBS and JW wrote the main manuscript text. All authors reviewed the manuscript.

Author information

Authors and Affiliations

  1. School of Public Health, Southeast University, No. 87, Dingjiaqiao Road, Nanjing, 21000, China

    Xiaobing Shen, Jia Wang, Xiaoluan Yan, Xiaofeng Ren, Fan Wang, Xiaowei Chen & Yuchao Xu

Authors
  1. Xiaobing Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jia Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xiaoluan Yan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xiaofeng Ren
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Fan Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Xiaowei Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yuchao Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xiaobing Shen.

Ethics declarations

Conflict of interest

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shen, X., Wang, J., Yan, X. et al. Predictive value of GSTP1 Ile105Val polymorphism in clinical outcomes of chemotherapy in gastric and colorectal cancers: a systematic review and meta-analysis. Cancer Chemother Pharmacol 77, 1285–1302 (2016). https://doi.org/10.1007/s00280-016-3047-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-016-3047-1

Keywords

Search

Navigation